Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study).

Francesca BaiChiara AldieriAnnaMaria CattelanFrancesca RaumerEugenia Di MecoMaria Cristina MoioliFederica TordatoPaola MorelliFederica BorghiMarco RizziEvelyn Van HauwermeirenFrancesco CastelliGuglielmo MigliorinoBarbara MenzaghiGiuliano RizzardiniAnnalisa SaracinoAntonio CascioMassimo PuotiAntonella d'Arminio MonforteGiulia Marchetti

Published in: Expert review of anti-infective therapy (2020)

Dalbavancin demonstrated a success rate of >80%, with similar efficacy/safety in ABSSSI and off-label indications. The preferential use of dalbavancin as second-line or combination therapy would seem to suggest the need for in-depth studies focused on its off-label use.

Keyphrases

combination therapy
liver failure
soft tissue
cross sectional
wound healing
big data
hepatitis b virus
respiratory failure
deep learning
replacement therapy